I n t r o d u c t i o n t o t h e P h a r m a c e u t i c a l I n d u s t r y

Transcription

1 I n t r o d u c t i o n t o t h e P h a r m a c e u t i c a l I n d u s t r y U n i v e r s i t y J o i n s I n d u s t r y M a r c h 1 5, J a v i e r T o r r e j ó n

2 Topics to be covered today.. History Drug$ Economics R&D.ThecoreoftheIndustry RISK Factors Current trends GALENICUM HEALTH 2

3 Introduction Develops, produces,& markets medicinal drugs Deal in generic&/or brand medications They are subject to a variety of laws & regulations regarding the patenting, testing& marketing of drugs GALENICUM HEALTH 3

4 History GALENICUM HEALTH 4

5 Some Important Events o!"#$%&'()*%+%,)-'$) '(A)B$6/)!&1)89CD<= o -2$,A)-'$)9)E B#+#,2F"#(1)2G)45)$#/6,'12$7)$6,#0 o -2$,A)-'$)H)3'(1%I%21%&0 o J'&&%(#0)3?"',,F2KL)M#((#$)89;C<=)3#$'A%&'1#A)%()9C;; o NO',%A2"%A#)89C<D=)3$#F2$1)'A+#$0#)A$6/)$#'&1%2(0 o!pb?)89c:d0=)3 G'01)1$'&Q)'FF$2+',R)SI67#$)F2T#$U o J%'/$')89CC:= o N'"%G,63V9W9)80T%(#)G,6=)F'(A#"%&)8HDDC= o WP*X)89CCC=)3 1O#)'GG2$A'I%,%17)G'&12$ o J%2KK3'(1%E%(G,'""'12$7)39CCCEHDDY)A6#)12),%1%/'1%2( o!+'(a%'3n7f#)h)8(2(e%(06,%()a#f#(a#(1=)a%'i#1#0)e9cccehd9d) ',02)A6#)12),%1%/'1%2( GALENICUM HEALTH 5

6 History of the Drugs o!"##$%&'($')*+,'-./$0)12%##3)14%$5)16"/0$170(/$ o 8&$0.*(#%/9#(:#(/;/0#) o :<%-"/0#=>?@AB1CD/0/0#=>?>EB1;<&;"/;/0#=>?F@B1-/&<;$%-/0#=>?GAB o H<%:<0#) o /0)D&/0=>EF>B1#).%$(/<&=>EFEB1.#).<).#%<0#=>EI>B1 J."#-/&&K=>EL@B o 40./5/<./;)18)';"<$;./9#(%D,)=-<).*>EMA.<>EL@N)B o -#0/;/&&/0=>EMMB1).%#-.<:';/0=>EMMB19$&/D:=>ELIB o!%#$.:#0.<o:#.$5<&/;(/)<%(#%)=>el@n).<;d%%#0.($'b o P#0.<&/0 =>ELEB1 Q/-/.<% =>EEGB1 P/$,%$ =>EE?B1 49$0(/$ =>EEEB1 P/<RR =>EEEB1 2&##9#;=F@@>B o S#$%;"O<%,#0#."#%$-/#)=>EE@B1).#:;#&&*5$)#(."#%$-/#) o S.#:*;#&&%#-&$;#:#0.<O$.%$;"#$=F@@?B GALENICUM HEALTH 6

7 DRUG$ GALENICUM HEALTH 7

8 Health expenditure as % of govt budget Percentage of government budget (%) Abuja Target 10,8 9,8 11,7 14,0 11,5 2 0 Low (36) Lower-middle (53) Upper-middle (56) High (52) Global (197) Income Group (# countries ) GALENICUM HEALTH 8

9 !"#$%&'()(*+&!,-"$&./"01"2%3-42"$&567%894-30%:&;<=)=> Country group (number of countries) Population Total Pharmaceutical Expenditure Millions % Million US$ % %THE %GDP Per capita (US$) WHO region Africa (43) % $19, % 23.0% 1.3% $10.59 Americas (35) % $436, % 19.8% 1.3% $87.30 Eastern Mediterranean (19) % $20, % 20.1% 1.2% $50.31 Europe (52) % $331, % 21.5% 1.6% $ South-East Asia (10) 1, % $41, % 33.2% 1.3% $13.05 Western Pacific (27) 1, % $276, % 18.7% 1.2% $37.90 World Bank income group High-income (49) 1, % $775, % 18.5% 1.4% $ Upper-middleincome (55) 2, % $283, % 21.2% 1.3% $96.78 Lower-middleincome (50) 2, % $59, % 23.6% 1.3% $26.28 Low-income (32) % $6, % 27.7% 1.6% $8.01 Global Global (186) 6,795 $1,125, % 1.4% $68.78 Source: World Health Organization Global Health Observatory Database, 2013 National Health Accounts, 2013 GALENICUM HEALTH 9

10 What is a drug$? A Chemical Substance that Interacts with a Living System and Produces a Biological Response GALENICUM HEALTH 10

11 What criteria MUST new drugs meet? o Drugs must address a new need or provide a significant added benefit over an existing medicine o Drugs must also meet five criteria: o Must be safe, effective, of high quality o cost effective (1980s) o.affordable (1990s) o REALLY affordable (2000+) GALENICUM HEALTH 11

12 Classification of Drug Types o Ethical drugs o Generic drugs (no longer under patent) o Prescription Only vs Over the Counter o Off Label applications o Orphan drugs o Biotechnology products o Counterfeit drugs o Street drugs! GALENICUM HEALTH 12

13 Economics GALENICUM HEALTH 13

14 Economics of the Pharmaceutical Industry Worldwide revenues > $980 billion/year Sales for the 10 largest drug companies: $297 billion in 2013 Greater than 5000 companies worldwide Top 5 companies have market shares about 4-5 % US = Largest markets (40 % of worldwide sales) GALENICUM HEALTH 14

15 The companies in 2013 Company Pfizer 48 Novartis 47 Roche 39 MSD 37 Sanofi 37 GSK 33 Jonhson & Jonhson 28 AstraZeneca 25 Lilly 21 AbbVie 18 $Billion s GALENICUM HEALTH 15

16 Economics 18.6% profit margin in % in 2000 ($24 billion) Largest of any industry 4 times greater than average return of all fortune 500 companies 8 out of 25 most profitable U.S. companies are pharmaceutical companies GALENICUM HEALTH 16

17 Mergers and Acquisitions Drug company mergers - Pfizer-Warner-Lambert, Upjohn-Pharmacia, Glaxo-Wellcome-SmithKline Beecham, etc. Pfizer acquired Pharmacia in 7/02 for $60 billion to become the worldns most powerful drug conglomerate. In 2015, Pfizer acquires Hospira GALENICUM HEALTH 17

18 Who pays the party? 55% out-of-pocket 25% private insurance 17% medicaid 3% Other (VA, WorkmanNs Comp, IHS, etc..) GALENICUM HEALTH 18

19 Where Prescription Money Go Research and development - 12% preclinical testing - 6% clinical testing - 6% Manufacturing and distribution - 24% Sales and marketing - 26% Administrative / miscellaneous expenses - 12% Taxes - 9% Net profit - 17% GALENICUM HEALTH 19

20 R&D. The core of the Industry GALENICUM HEALTH 20

21 The Pay Off to the companies o R&D = 15 to 25 % of sales turnover o Patent protection 20 years from filing o On average, 11yrs. of productive market life o Losec $2.7Bn in 1998; Nexium (single enantiomer) $7.7Bn in 2008 o Lipitor - $1Bn in 1998; $13.8Bn in 2008 GALENICUM HEALTH 21

22 Cost of launching an NCE continues to rise 25th percentile 75th percentile Average Standard deviation Standard error Industry (n=20) $M !"#$%&'()*+(,-.&$-/.0"-/1(2(345*!56(+7837+! GALENICUM HEALTH 22

23 Pharmaceutical Industry Facts Revenues from approved drugs (1 of 5 to 10,000) must cover the Jdry holesk of non approved compounds. Average cost of bringing a drug to market is 1000 million dollars. Average approval time is 12 to 15 years. Time to recoup investment is shrinking- generic drugs and limited patent life GALENICUM HEALTH 23

24 Pharma Industry: Innovators vs. Generics Except BQ Except BQ Generic Innovator GALENICUM HEALTH 24

25 Pharmaceutical Industry Facts Generics High competition Price Pressure Short product lifecycle Same regulatory requirements GALENICUM HEALTH 25

26 Pharmaceutical Industry Facts Generics GALENICUM HEALTH 26

27 R&D for Pharmaceuticals and Other Industries (% of Sales) Z#0#'$&OEI'0#A)[O'$"'&#61%&',)*2"F'(%#0\,-9#:.$0/1(!&%."$()";</$0:"-' B$6/0)'(A)d#A%&%(#\ cgg%&#)xf6%f"#(1)'(a)?#$+%&#0 X,#&1$%&',)'(A)X,#&1$2(%&0 N#,#&2""6(%&'1%2(0.#%06$#)N%"#)[$2A6&10!612"21%+#!#$20F'&#)'(A)B#G#(0# d#1',0)'(a)d%(%(/ D]C^ D]C^ <]D^ _]9^ Y]C^ Y]9^ `];^ ;]<^ 9H]D^ HD]:^!,,)P(A601$%#0R)XK&,6A%(/)B$6/0)'(A)d#A%&%(# `];^ \ Z#0#'$&OEI'0#A)[O'$"'&#61%&',)*2"F'(%#0 a'0#a)2()x1o%&',)[o'$"'&#61%&',)?',#0)'(a)x1o%&',)[o'$"'&#61%&',0)zbb) c(,7)'0)n'i6,'1#a)i7)[ozd!>) B$6/0)'(A)d#A%&%(#?#&12$)'0)N'I6,'1#A)I7)?1'(A'$A)b)[22$ 0)*2"F601'1R)') B%+%0%2() 2G)d&e$'TEV%,,)?26$&#L)[OZd!R)9CCCR)a'0#A)2()B'1')@$2")[OZd!!((6',)?6$+#7)'(A)?1'(A'$A)b)[22$ 0)*2"F601'1R)')B%+%0%2() 2G)d&e$'TEV%,, GALENICUM HEALTH 27

28 Compound Success Rates: 1 in 10,000 Reach FDA Approval Phase I Healthy Volunteers Used to Determine Safety and Dosage Phase II Patient Volunteers Used to Look for Efficacy and Side Effects Phase III 1,000 5,000 Patient Volunteers Used to Monitor Adverse Reactions to Long-term Use Discovery (2 10 Years) Preclinical Testing Laboratory and Animal Testing Compound Success Rates by Stage 5,000 10,000 Screened 250 Enter Preclinical Testing 5 Enter Clinical Testing FDA Review/Approval Additional Postmarketing Testing Approved by the FDA Source: PhRMA, Based on Data From the Tufts Center for the Study of Drug Development, 1995 GALENICUM HEALTH 28

29 Top 10 Therapies - sales in 2008 (US$Bn) 2008 sales % share Oncology agents Lipid regulators Respiratory agents Acid pump inhibitors Antidiabetics Antipsychotics Angiotensin antagonists Antidepressants US$227.8Bn 32.1% GALENICUM HEALTH 29

30 Decreasing Costs Formularies Generics Volume discounts/mail order prescriptions Patient -e.g., AIDS/ACT UP activism GALENICUM HEALTH 30

31 Drug Reimbursement Systems Copayments income exempted groups variation Cost-sharing Expenditure limits Positive and negative prescribing lists Therapeutic efficacy categories GALENICUM HEALTH 31

32 COST Perspective What is the cost if pharmaceutical manufacturers did not create revolutionary drugs.. GALENICUM HEALTH 32

33 COST of Uncured Disease States GALENICUM HEALTH 33

34 The Pay Off.to us o Massive contributions to health, quality of life, reduced child mortality, life expectancy o Vaccines have eradicated major disease smallpox; vaccines for malaria and pneumonia soon..? o But costs and accessibility to healthcare are becoming major social and geopolitical issues o And, is there something seedy about making money out of illness? o What will happen into the future? GALENICUM HEALTH 34

35 RISK Factors GALENICUM HEALTH 35

36 Vioxx $2.5 Billion annual sales in #1 arthritis and acute pain medicine outside the US -#2 in the US Use >18months will cause heart attack and stoke Voluntarily withdraw worldwide (Sep 30, 2004) share price dropped from $45.07 to $33.00(one day) $27 billion in market cap was erased GALENICUM HEALTH 36

37 Vioxx 9,650 Vioxx liability lawsuits has been filed (Dec 31, 2005) 19,100 plaintiffs has involved (Dec 31, 2005) The company spent $285 Million in legal defense during 2005 Increase the reserve amount to $685 Million for legal fees through 2006 and 2007 (Dec 2005) Unpredictable outcomes in lawsuits, substantial damages, fines, criminal penalties GALENICUM HEALTH 37

38 Other Risk Factors Failure in developing and acquiring commercially successful products Failure in regulatory approval Competition from other products 1) More efficiency 2) price pressure Unexpected future changes in government laws and regulations GALENICUM HEALTH 38

39 Too many companies, too few products Molecules Losing Exclusivity in Germany and USA US LoE German LoE?26$&#L)W#TF2$1)V2$%g2()[$#"%6"h)i)NVcd?cW)ZX4NXZ? GALENICUM HEALTH 39

40 Current Trends GALENICUM HEALTH 40

41 Trends of the Market Arthritis 46 million adults (non-institutionalized) in the U.S. (2003) 21% of adults (non-institutionalized) in the U.S. (2003) Cancer 23 million suffering worldwide. Estimated of 1.37 million people in the US were diagnosed with cancer in 2005 about 1 in 3 lifetime risk; 38% of women and 43% of men The average cost of cancer treatment is well over $100,000 per person. Estimated $280 billion spent on treatment drugs for cancer annually. More than $100 Billions in US Diabetes Estimated 18.2 million people in the United States, or 6.3% of the population (2005) 165 million cases worldwide (2003) $132 billion spent in direct and indirect costs in America (2002) Heart Disease 25 million adults in the US Heart disease and stroke cost US around $214 billion annually. ($115 billion direct) (2002) GALENICUM HEALTH 41

42 US NCE Approvals ?26$&#L)W#TF2$1)V2$%g2()[$#"%6"h)i)NVcd?cW)ZX4NXZ? GALENICUM HEALTH 42

43 Current pipeline activity looks to continue the trend US Germany Phase III Pre-Registration Registered!"#$%&'(3=";:"-(>=/$;/(2(NVcd?cW)ZX4NXZ? GALENICUM HEALTH 43

44 Jobs Opportunities in Pharmaceutical Industry It includes many job opportunities of pharmacists: Drug discovery Manufacturing Marketing Medical information Product development Quality assurance Training & development Sales Regulatory Project management Health outcomes research Legal (e.g. IP) Information technology Scientific communications GALENICUM HEALTH 44

45 Jobs Opportunities in Pharmaceutical Industry It includes many job opportunities of pharmacists: Patience Attention to detail Decisiveness Independence Excellent IT skills Numerical skills Analytical skills Teamworking skills Languages GALENICUM HEALTH 45

46 Jobs Opportunities in Pharmaceutical Industry Solution selling Focus on other party problems Be solution to the problems No problems by yourself GALENICUM HEALTH 46

47 GALENICUM HEALTH 47